Transgenically produced antithrombin III

Details Transgenically produced antithrombin III Transgenically produced antithrombin III

2011-04-19

2011-04-19

Crouch, Deborah (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S393000

Reexamination Certificate

active

07928064

ABSTRACT:
This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

REFERENCES:
patent: 4517294 (1985-05-01), Bock et al.
patent: 4632981 (1986-12-01), Bock et al.
patent: 4873316 (1989-10-01), Meade et al.
patent: 5366894 (1994-11-01), Clark et al.
patent: 5843705 (1998-12-01), DiTullio et al.
patent: 6441145 (2002-08-01), DiTullio et al.
patent: 7019193 (2006-03-01), Ditullio et al.
patent: 0 475 354 (1991-10-01), None
Menache et al. Evaluation of the Safety, Recovery, Half-Life, and Clinical Efficacy of Antithrombin III (Human) in Patients with Hereditary Antithrombin III Deficiency. Blood. vol. 75, pp. 33-39.
Cole et al. Glycosylation Patterns of Human Proteins Expressed in Transgenic Goat Milk. Journal of Ceilluar Biochemistry. 1994, Suppl. 18D, p. 265, Ab. U100, published online Feb. 19, 1994.
Bock, S. et al., “Cloning and Expression of the cDNA for Human Antithrombin III”,Nucleic Acids Research, vol. 10 (24), pp. 8113-8125 (1982).
Cole, E. et al., “Glycosylation Patterns of Human Proteins Expressed in Transgenic Goat Milk”,), pp.I of Cellular Biochemistry, Supp. 0 (180D), pp. 265 (1994).
Edmunds, T. et al., “Tissue Specific and Species Differences in the Glycosylation Pattern of Antithrombin III”,Journal of Cellular Biochemistry, Supp. 0 (180D), pp. 265 (1994).
Fan, B. et al., “Heterogeneity of Recombinant Human Antithrombin III Expressed in Baby Hamster Kidney Cells”,The Journal of Biological Chemistry, vol. 268 (23), pp. 17588-17596 (1993).
Wall, R., “Transgenic Livestock: Progress and Prospects for the Future”,Theriogenology, vol. 45, pp. 57-68 (1996).
Denman et al., “Transgenic expression of a variant of human tissue-type Plasminogen activator in goat milk: purification and characterization of the recombinant . . . ” Biotechnology, 9:839-843, 1991.
Ebert et al., “Transgenic production of a variant of human tissue-type Plasminogen activator in goat milk: generation of transgenic goats and analysis . . . ” Biotechnology, 9:836-838, 1991.

Affiliated with

Also associated with

Rating

Transgenically produced antithrombin III does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transgenically produced antithrombin III, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenically produced antithrombin III will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2694914